Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial

Overview of attention for article published in Journal of Clinical Oncology, June 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 6 news outlets
blogs: 1 blog
policy: 1 policy source
twitter: 36 X users

facebook: 1 Facebook page
wikipedia: 1 Wikipedia page
guideline: 4 clinical guideline sources

Readers on

mendeley: 245 Mendeley

So far, Altmetric has seen 1 policy document that references this research output.

Lutathera for Gastroenteropancreatic neuroendocrine tumors – Details - Lutetium Lu 177 dotatate (Lutathera) GEP-NET – Final Clinical Guidance Report

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 30 Jul 2018

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.